Novel benzothienyl amino (propyl and butyl) ketones

ABSTRACT

Compounds having the formula ##STR1## wherein R 1  and R 2  are alkyl having one to 4 carbon atoms, allyl or ##STR2## is pyrrolidino, piperidino, perhydroazepino or morpholino, RX is an inorganic acid, organic acid or an alkyl bromide or iodide, m is 3 or 4, and n is zero or one. The compounds are prepared by (1) reacting benzothienyl-lithium with ##STR3## followed by hydrolysis, or (2) when the substituent is located at the 2 position of the benzothienyl group, by reacting benzothiophene with ##STR4## followed by reaction with ##STR5## The compounds possess bloodplaque aggregation, spasmolytic, analgesic, anti-inflammatory and coronary, cerebral and peripheral vaso-dilatory properties.

This is a division of application Ser. No. 672,109, filed Mar. 31, 1976now U.S. Pat. No. 4,186,136.

The present invention has at its object novel benzothienyl amino propyland butyl ketones, a method of preparation thereof and their applicationin therapeutics.

The compounds of the invention have the general formula: ##STR6## where:R₁ and R₂ designate each an alkyl radical saturated or not having 1 to 4carbon atoms of form together with the nitrogen atom to which they arebound a heterocyclic radical chosen from the following: pyrrolidino,piperidino, perhydroazepino and morpholino; and

HX represents an acid compound chosen from the following:

hydrochloric acid, bromhydric acid, sulphuric acid, phosphoric acid,boric acid;

oxalic, maleic, malic, fumaric, citric, embonic, methane sulfonic,acetylsalicylic, nicotinic, parachlorophenoxyacetic orparachlorophenoxyisobutyric acid;

methyl bromide, methyl iodide, ethyl bromide, butyl bromide, benzylbromide;

m is worth 3 or 4; and

n represents 0 or 1.

The method of the invention comprises the following succession ofoperations:

reaction of bromobenzothiophene of formula (II) ##STR7## onn.butyl-lithium of formula (III):

    n.C.sub.4 H.sub.9 --Li                                     (III)

to give benzothienyl-lithium of formula (IV) ##STR8## addition of anaminoalkylnitrile of formula (V) ##STR9## where R₁, R₂ and m have thesame significance as in formula (I), on the benzothienyl-lithiumpreviously obtained to produce a compound of formula (VI) ##STR10##which is hydrolised to finish up directly with the ketone of formula (I)##STR11## which may be subjected to a salification by an acid compoundof formula HX defined above,

which gives salts of formula ##STR12## It is also possible to preparecompounds of formula (I'): ##STR13## where R₁, R₂, HX, m and n have thesame significance as above, by the following succession of operations:

condensation of a chlorated acid chloride of formula (VII) ##STR14##where m is worth 3 or 4, on benzothiophene of formula (VIII): ##STR15##in the presence of a Lewis acid, from which results the chlorated ketoneof formula (IX): ##STR16## followed by a condensation of amine offormula (X) ##STR17## where: R₁ and R₂ have the same value as in formula(I) on said compound of formula (IX)

to give the basis of formula (I) ##STR18## which may be subjected tosalification by an acid compound of formula HX such as defined above.

The following preparations are given as examples.

EXAMPLE 1: 1-(benzothien-2'-yl)-4-N-morpholino butanone

A solution of n-butyl lithium in 100 ml of anhydrous diethylic ether isprepared at 0° C. from 14 g of lithium and 14 g of n-butyl bromide. Asolution of 13 g of 2-bromo benzothiophene in 50 ml of diethylic etheris slowly added with agitation, under nitrogen and at a temperature of-20° C. Agitation continues for two hours. 15 g of 4-N-morpholinobutyronitrile is poured in. Agitation is carried out for 16 hours at-20° C. Hydrolysis is carried out by pouring with agitation on to 150 gof piled ice. The ether is decanted and the aqueous phase extracted withether. The united etherated phases are dried on disodic sulfate and thesolvent is evaporated. The residue is recrystallized in cyclohexane.

Thus is obtained, with a yield of 60%, white crystals having a meltingpoint of 61° C.

EXAMPLE 2: 1-(benzothien-2'-yl)-4-N-morpholino butanone hydrochloride

Compound 1 in basic form is transformed into hydrochloride by saturationwith a flow of gaseous hydrochloric acid of its solution in ethylicether.

The resulting product is in the form of white crystals having a meltingpoint of 172° C.

EXAMPLE 3: 1-(benzothien-2'-yl)-4-N,N-diallylamino butanone oxalate

A mixture of 4.6 g of 1-(benzothien-2'-yl)-4-chloro butanone and 1.8 gof diallylamine is heated at reflux for 10 hours. After cooling, 250 mlof water are added to the reaction product, which is alkalysed byaddition of soda and extracted with diethylic ether. The ether is driedon disodic sulfate and evaporated. The oily residue is dissolved in theminimum of acetone and heated to reflux for 30 minutes with a solutionof 3 equivalents of oxalic acid in acetone. Centrifugation is carriedout after cooling and recrystallization in acetonitrile.

Thus are obtained, with a yield of 60%, white crystals having a meltingpoint of 172° C.

The compounds shown in the following tables I and II were prepared inthe same way.

                                      TABLE I                                     __________________________________________________________________________     ##STR19##                                                                     compoundNo. of                                                                      m                                                                               ##STR20##                                                                               HX   (°C.)pointMelting                                                           solventRecrystallisation                                                                (%)Yield                               __________________________________________________________________________    4     3                                                                                ##STR21##                                                                             chlorhydric acid                                                                     180 Acetonitrile                                                                             70                                     5     3                                                                                ##STR22##                                                                             chlorhydric acid                                                                     186 Methanol   70                                     6     3                                                                                ##STR23##                                                                             citric acid                                                                          168 Acetonitrile (1) + methanol                                                              50)                                    7     3                                                                                ##STR24##                                                                             p. chloro- phenoxyiso butyric acid                                                   159 petroleum ether (1) ethylic ether                                                        40)                                    8     4 N(C.sub.3 H.sub.7)2                                                                    methyl 142 Acetonitrile                                                                             40                                                      iodide                                                       __________________________________________________________________________

                                      TABLE II                                    __________________________________________________________________________     ##STR25##                                                                     poundcom-No. of                                                                   ##STR26##                                                                               HX    (°C.)pointMelting                                                           tion solventRecrystallisa-                                                              (%)Yield                                  __________________________________________________________________________     9                                                                                 ##STR27##                                                                              bromhydric acid                                                                     138  absolute ethanol                                                                        65                                         10                                                                                 ##STR28##                                                                              p.chloro- phenoxy- isobutyric acid                                                  180  petroleum ether                                                                         65                                         11                                                                                 ##STR29##                                                                              bromhydric acid                                                                     167  Acetonitrile                                                                            60                                         12                                                                                 ##STR30##                                                                              bromhydric acid                                                                     165  Acetronitrile (1) +  methanol (3)                                                       60                                         13                                                                                 ##STR31##                                                                              bromhydric acid                                                                     178  methanol  70                                         14                                                                                 ##STR32##                                                                              bromhydric acid                                                                     227  methanol  70                                         15                                                                                 ##STR33##                                                                              bromhydric acid                                                                     146  Acetonitrile                                                                            75                                         16                                                                                 ##STR34##                                                                              citric acid                                                                         162  Acetonitrile                                                                            75                                         17                                                                                 ##STR35##                                                                              bromhydric acid                                                                     186  Acetonitrile (2) + methanol (1)                                                         65                                         __________________________________________________________________________

The compounds of formula (I) were tested on laboratory animals andshowed themselves particularly active as blood-plaque aggregationinhibitors. They also showed an appreciable activity as spasmolytic,analgesic, anti-inflammatory agents and coronary, cerebral andperipheral vaso-dilatators.

1. Acute toxicity

The acute toxicity of the compounds of formula (I) were evaluated orally(esophagean probe) on a mouse deprived of food 18 hours before thebeginning of the test. The products were placed in suspension in asolution of dilute carboxymethyl cellulose. Calculation of the 50 lethaldose (LD 50) was effected according to the method of Miller and Tainter(Miller L. C., Tainter M. L., Proc. Soc. Exptl. Biol. Med. 1944, 57,261-264).

The death rate was checked for seven days following the treatment.

Table III gives the 50% lethal doses (LD 50) in milligrams per kilogrambody weight.

                  TABLE III                                                       ______________________________________                                                             LD 50                                                    No. of compound      (mg/kg/p.o.)                                             ______________________________________                                        1                    1 200                                                    2                    1 500                                                    4                    950                                                      5                    1 300                                                    9                    >1 200                                                   10                   1 100                                                    11                   1 100                                                    12                   500                                                      13                   760                                                      14                   850                                                      15                   950                                                      16                   1 200                                                    17                   1 000                                                    ______________________________________                                    

2. Activity on blood-plaque aggregration

The blood plaques used for these studies were human blood-plaquesintroduced into the test in the form of blood-plaque rich plasmas(B.P.R.P.).

These latter were obtained as water-repellent material by slowcentrifugation from human blood samples.

The study of blood-plaque aggregation was made by means of anaggregate-meter with continuous agitation and graphic recordingaccording to the conventional method. (PROST R. S., SOUVERAIN C. H.,DOUMENC J., Etude de l'agregation plaquettaire a l'aide de l'agregametrede MUSTARD--Coagulation, 1971, 4, 2, 145-151).

The agents employed for inducing aggregation were diphosphoric adenosineacid (D.P.A.), 1-(3',4'-di-hydroxyphenyl)-2-methylamino ethanol(adrenaline) and collagene. All these reactants were prepared frommother solutions diluted in a Michaelis' buffer. Their concentration inthe test may vary according to the affinity of the blood-plaques.

An optimum concentration is thus sought by successive tests on the sameB.P.R.P.

The inhibitory activity on the aggregation was evaluated by addition ofthe product under study to the B.P.R.P. before introduction of theaggregating agent.

The concentrations of compounds of formula I(X) in the B.P.R.P. are:C(X)=2.5×10⁻⁵ g/ml for aggregation with D.P.A. and adrenaline, and C(X)=2×10⁻⁵ g/ml for collagene.

The reference product (R) is2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyramidine (knownunder the trademark "Dipyridamole") used in the concentration C(R)=5×10⁻⁴ g/ml for aggregation with D.P.A. and adrenaline and C(R)=2×10⁻⁴ g/ml for aggregation with collagene.

The following table IV indicates the activity of some compounds offormula I: a (X) the activity of the reference product: a (R) and thedifferent values of the ratio: ##EQU1##

In addition, in order to ensure a better comparison between the activityof the compounds of the invention and that of the reference product,Table IV shows the values of the ratio ##EQU2##

We get: LD 50 (R)=2150 mg/kg/p.o.)

                                      TABLE IV                                    __________________________________________________________________________     Inhibitory activity of the blood-plaque aggregation                          __________________________________________________________________________    No. of                                                                              D.P.A.      D.P.A. or ADRENALINE                                                                        ADRENALINE                                    compound tested                                                                     a(X) (%)                                                                         a(R) (%)                                                                          ##STR36##                                                                           ##STR37##    a(X) (%)                                                                         a(R) (%)                                                                          ##STR38##                              __________________________________________________________________________    1     -- -- --    8.9 × 10.sup.-2                                                                        9 91  1 × 10.sup.-1                    2     -- -- --    7.2 × 10.sup.-2                                                                       15 91 1.65 × 10.sup.-1                  3     15 87 1.7 × 10.sup.-1                                                               --            -- -- --                                      4     -- -- --    1.1 × 10.sup.-1                                                                       78 78 1                                       5      8 53 1.5 × 10.sup.-1                                                               8.3 × 10.sup.-2                                                                       84 78 1.1                                     6     15 87 1.7 × 10.sup.-1                                                               --            -- -- --                                      9     15 79 1.9 × 10.sup.-1                                                               <9 × 10.sup.-2                                                                        86 86 1                                       11    10 55 1.8 × 10.sup.-1                                                               10.sup.-1     51 88 5.8 × 10.sup.-1                   12    29 79 3.6 × 10.sup.-1                                                               2.15 × 10.sup.-1                                                                      80 88 9.1 × 10.sup.-1                   13    18 79 2.3 × 10.sup.-1                                                               1.4 × 10.sup.-1                                                                       84 77 1.1                                     14    -- -- --    1.3 × 10.sup.-1                                                                       42 77 5.5 × 10.sup.-1                   15    17 85 2 10.sup.-1                                                                         1.15 10.sup.-1                                                                              82 86 9.5 × 10.sup.-1                   16    47 85 5.5 × 10.sup.-1                                                                9 × 10.sup.-2                                                                        -- -- --                                      __________________________________________________________________________               No. of                                                                              COLLAGENE                                                               compound tested                                                                     a(X) (%)                                                                         a(R) (%)                                                                          ##STR39##                                                                            ##STR40##                                      __________________________________________________________________________               1     12 36 3.3 × 10.sup.-1                                                                1.8 × 10.sup.-1                                      2     12 36 3.3 × 10.sup.-1                                                                1.4 × 10.sup.-1                                      3     13 67 1.95 × 10.sup.-1                                                               --                                                         4     39 88 4.5 × 10.sup.-1                                                                2.3 × 10.sup.-1                                      5     12 88 1.4 × 10.sup.-1                                                                1.7 × 10.sup.-1                                      6     32 93 3.5 × 10.sup.-1                                                                --                                                         9     16 51  3 × 10.sup.-1                                                                 1.8 × 10.sup.-1                                      11    12 36 3.3 × 10.sup.-1                                                                1.95 × 10.sup.-1                                     12    12 53 2.3 × 10.sup.-1                                                                4.3 × 10.sup.-1                                      13    -- -- --     --                                                         14    -- -- --     --                                                         15    -- -- --     --                                                         16    92 36 2.5    1.8 × 10.sup.-1                           __________________________________________________________________________

This table shows that, taking into account the value of the ratio##EQU3## the inhibitory activity of the blood-plaque aggregation of thecompounds of the invention is at least equal to that of the referenceproduct. For certain compounds, such as No. 17, it is even substantiallysuperior.

3. Spasmolytic activity

The spasmolytic activity was studied on a rat's isolated duodenummaintained in a survival medium of an aerated Tyrode solution heated to38° C. according to the technique of Magnus (Magnus R.-Archivs ges.Physiol., 1905, 180, 1-71).

The contracting agent used was barium chloride, the reference antagonistagent being papaverine hydrochloride (R). The average activity of thecompounds of formula I (X) in comparison with that of the referenceagent was expressed by calculating the ratio of the 50 efficient doses(ED 50) determined graphically on logarithmic paper: ##EQU4##

For example: a substance having a relative activity expressed by theFIG. 2 presents an activity equal to twice that of papaverinehydrochloride.

The results obtained, given in table V, show that the compounds of theinvention have an interesting spasmolytic activity.

                  TABLE V                                                         ______________________________________                                        Spasmolytic activity                                                          No. of   Spasmolytic activity                                                 compound tested                                                                        ED 50 (X) (g/ml)                                                                          ED 50 (R) (g/ml)                                                                           ##STR41##                                   ______________________________________                                         3       1.2 × 10.sup.-6                                                                     2.5 × 10.sup.-6                                                                     2.08                                          9       0.5 × 10.sup.-6                                                                     4.05 × 10.sup.-6                                                                    8.10                                         10       3.8 × 10.sup.-6                                                                     4 × 10.sup.-6                                                                       1.05                                         11       1.05 × 10.sup.-6                                                                    6.5 × 10.sup.-6                                                                     6.2                                          12       1.35 × 10.sup.-6                                                                    6.5 × 10.sup.-6                                                                     4.8                                          13       2.25 × 10.sup.-6                                                                    3.5 × 10.sup.-6                                                                     1.55                                         15       3 × 10.sup.-6                                                                       4.75 × 10.sup.-6                                                                    1.6                                          16       1.5 × 10.sup.-6                                                                     4 × 10.sup.-6                                                                       2.7                                          17       2.15 × 10.sup.-6                                                                    7.25 × 10.sup.-6                                                                    3.4.                                         ______________________________________                                    

4. Analgesic and anti-inflammatory activity

The intraperitoneal injection of phenylparaquinone (P.P.Q.) in a mousecauses the appearance of a painful syndrome appearing within 5 minutesof the injection and disappearing after about 30 minutes (SIEGMUND E.A., CADMUS A., LU G., J. Pharmacol, Exp. Therap. 1957, 119, 453). Thispainful syndrome manifests itself in the animal by a series ofcharacteristic crises, more or less close together and fleeting, duringwhich we can note a twisting or stretching of the body, a hollowing ofthe sides and a stretching of the hind legs.

It is therefore possible to note the number of crises in a giveninterval of time.

The preventive administration of analgesic or anti-inflammatorysubstances prevents the appearance of crises or reduces the frequencythereof.

The reference substance (R) used in the tests was the ester ofN-(7-chloro-4 quinolyl) anthranilic acid and 2,3-dihydroxy n.propanol(known under the trademark Glafenine).

It was administered orally with a dose of 25 mg/kg.

The compounds of formula I (X) were administered digestively with a doseof 50 mg/kg.

The interval of time (t) which was chosen to evaluate the analgesicactivity was between 10 and 15 minutes which is the period of maximumfrequency of the crises. This activity was expressed in the followingway:

n: number of crises observed in the control mice;

n': number of crises observed in mice previously treated with thereference substance (R);

n": number of crises observed in mice having received the substance (X).

The percentage activity of R is equal to ##EQU5##

The percentage activity of X is equal to ##EQU6## The activity of X inrelation to that of R is estimated by the ratio ##EQU7## For example: acompound X for which ##EQU8## is 0.5 has an activity equal to half thatof the reference product.

Table IV following gives the results observed.

In addition, so as to permit a better appreciation of the compounds ofthe invention table VI shows the values of the ratio:

                  TABLE VI                                                        ______________________________________                                        Analgesic and anti-inflammatory activity                                               Analgesic and anti-                                                  No. of   inflammatory activity                                                compound tested                                                                         a(X)    a(R)                                                                                  ##STR42##                                                                              ##STR43##                                  ______________________________________                                         2       38      75      5 × 10.sup.-1                                                                    3.3 × 10.sup.-2                        6       55      77      7 × 10.sup.-1                                                                    --                                           9       47      45      1        <4.2 × 10.sup.-2                      11       48      75        6.5 × 10.sup.-1                                                                4.5 × 10.sup.-2                       12       68      45      1.5       10 × 10.sup.-2                       14       39      74        5.3 × 10.sup.-1                                                                5.9 × 10.sup.-2                       15       51      45      1.13     5.3 × 10.sup.-2                       16       44      75        5.9 × 10.sup.-1                                                                4.2 × 10.sup.-2                       17       55      45      1.2        5 × 10.sup.-2                       ______________________________________                                    

This table shows that for a dose administered corresponding to a smallfraction of the lethal dose some compounds of formula I have ananalgesic and anti-inflammatory activity similar to that of thereference product.

Other compounds have an activity representing approximately 6/10 that ofR. This activity must nevertheless be considered interesting since thereference product is a particularly active analgesic.

5. Vaso-dilatatory activity

The vaso-dilatatory activity as regards the smooth musculature of thevessels was demonstrated on the isolated heart of a gumea-pig perfusedwith a Locke solution maintained at 37° C. after providing the aortawith a cannula.

The coronary flow is recorded, by means of an electronic device fittedwith a Fleish totaliser, before and after addition of the substance Xunder study (concentration: 1×10⁻⁵ g/ml), the reference product (R)being 2,6-bis(diethanolamino)4,8-dipiperidinopyrimido[5,4-d]pyrimidine(known under the trademark "Dipyridamole") used at a concentration of1×10⁻⁵ g/ml.

The percentage flow increase P was calculated at the climax of theactivity of X or R.

Table VII below gives, as examples, the results observed with somecompounds of formula I.

                  TABLE VII:                                                      ______________________________________                                        Vaso-dilatatory activity                                                      Code No. of compound tested                                                                 P (X)      P (R)                                                                                   ##STR44##                                  ______________________________________                                         1           28         43        6.5 × 10.sup.-1                       10           60         43        1.4                                         11           41         53         7.75 × 10.sup.-1                     12           33         53         6.25 × 10.sup.-1                     15           172        71        2.42                                        ______________________________________                                    

This table shows that the vaso-dilatatory activity of the products ofthe invention ranges from 0.6 to 2.5 times that of the referenceproduct.

These pharmacological results show the interest of the formula Icompounds in the treatment of coronary and cardiac insufficiencies,pains of inflammatory and other origins, and spasms.

Formula I compounds can be administered to man and animals orally,rectally or parenterally, particularly associated with the appropriateexcipient in each case.

As examples, they may be presented in the form of tablets, pills,gelules, suppositories or injectable solutions.

The daily dosage may, according to the case, range from 50 to 600 mg.

What we claim is:
 1. A compound having the formula ##STR45## wherein R₁and R₂ are alkyls having 1 to 4 carbon atoms or allyl;HX is selectedfrom the group consisting of hydrochloric acid, bromhydric acid,sulfuric acid, phosphoric acid, boric acid, oxalic acid, maleic acid,malic acid, fumaric acid, citric acid, embonic acid, methanesulfonicacid, acetylsalicylic acid, nicotinic acid, parachlorophenoxyaceticacid, parachlorophenoxyisobutyric acid, methyl bromide, methyl iodide,ethyl bromide, butyl bromide and benzyl bromide; m is 3 or 4; and n is 0or
 1. 2. A compound as claimed in claim 1 having the formula ##STR46##3. A compound as claimed in claim 2 in which R₁ and R₂ are allyl, HX isoxalic acid and n is
 1. 4. A compound as claimed in claim 2 in which R₁and R₂ are methyl, HX is hydrochloric acid and n is
 1. 5. A compound asclaimed in claim 1 having the formula ##STR47## wherein HX is methyliodide.
 6. A compound as claimed in claim 1 having the formula ##STR48##7. A compound as claimed in claim 6 in which R₁ and R₂ are ethyl, HX isbromhydric acid or p-chlorophenoxyisobutyric acid, and n is
 1. 8. Acompound as claimed in claim 6 in which R₁ and R₂ are propyl, HX isbromhydric acid and n is
 1. 9. A compound as claimed in claim 6 in whichR₁ and R₂ are --CH(CH₃)₂, HX is bromhydric acid and n is 1.